Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay

P. M. Bayer, S. Bauerfeind, J. Bienvenu, N. Fabien, P. C. Frei, B. Gilburd, K. G. Heide, M. Hoier-Madsen, P. L. Meroni, J. C. Monier, G. Monneret, P. Panzeri, Y. Shoenfeld, F. Spertini, A. Wiik

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The COBAS® Core HEp2 ANA enzyme immune assay (EIA) was evaluated in a precision and a clinical sample study in comparison to indirect immunofluorescence assay (IFA) on HEp2-cells. In the precision study the COBAS® Core EIA yielded intraassay coefficient variations (CVs) mostly below 9%, and interassay CVs between 4.7% and 10.4%. When comparing the COBAS® Core EIA to IFA, the results corresponded well in healthy subjects, systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. In the case of Sjogren's syndrome and scleroderma patients the COBAS® Core EIA yielded a lower rate of positive results compared to IFA. This discrepancy may be explained by the lack of detection of autoantibodies to nuclear antigens that can be identified only by IFA due to their compartimentalization and higher localized antigen density in HEp2 cells. The discrepancies in the group of dermato/polymyositis patients are due to the fact that the EIA contains mainly nuclear antigens and was able to detect only antibodies against the cytoplasmic Jo1 antigen that was added to the HEp2 nuclear extract. Routine sera were also evaluated; good agreement was found in sera from patients attending tertiary reference centres for autoimmune diseases but a higher number of discrepancies was reported in sera from unselected populations.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalJournal of Autoimmunity
Volume13
Issue number1
DOIs
Publication statusPublished - Aug 1999

Fingerprint

Enzyme Assays
Multicenter Studies
Fluorescent Antibody Technique
Nuclear Antigens
Serum
Mixed Connective Tissue Disease
Antigens
Polymyositis
Sjogren's Syndrome
Indirect Fluorescent Antibody Technique
Systemic Lupus Erythematosus
Autoantibodies
Autoimmune Diseases
Rheumatoid Arthritis
Healthy Volunteers
Antibodies
Population

Keywords

  • Antinuclear antibodies
  • Enzyme immunoassay
  • Systemic autoimmune diseases

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Bayer, P. M., Bauerfeind, S., Bienvenu, J., Fabien, N., Frei, P. C., Gilburd, B., ... Wiik, A. (1999). Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay. Journal of Autoimmunity, 13(1), 89-93. https://doi.org/10.1006/jaut.1999.0298

Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay. / Bayer, P. M.; Bauerfeind, S.; Bienvenu, J.; Fabien, N.; Frei, P. C.; Gilburd, B.; Heide, K. G.; Hoier-Madsen, M.; Meroni, P. L.; Monier, J. C.; Monneret, G.; Panzeri, P.; Shoenfeld, Y.; Spertini, F.; Wiik, A.

In: Journal of Autoimmunity, Vol. 13, No. 1, 08.1999, p. 89-93.

Research output: Contribution to journalArticle

Bayer, PM, Bauerfeind, S, Bienvenu, J, Fabien, N, Frei, PC, Gilburd, B, Heide, KG, Hoier-Madsen, M, Meroni, PL, Monier, JC, Monneret, G, Panzeri, P, Shoenfeld, Y, Spertini, F & Wiik, A 1999, 'Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay', Journal of Autoimmunity, vol. 13, no. 1, pp. 89-93. https://doi.org/10.1006/jaut.1999.0298
Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gilburd B et al. Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay. Journal of Autoimmunity. 1999 Aug;13(1):89-93. https://doi.org/10.1006/jaut.1999.0298
Bayer, P. M. ; Bauerfeind, S. ; Bienvenu, J. ; Fabien, N. ; Frei, P. C. ; Gilburd, B. ; Heide, K. G. ; Hoier-Madsen, M. ; Meroni, P. L. ; Monier, J. C. ; Monneret, G. ; Panzeri, P. ; Shoenfeld, Y. ; Spertini, F. ; Wiik, A. / Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay. In: Journal of Autoimmunity. 1999 ; Vol. 13, No. 1. pp. 89-93.
@article{f824d56880834d05a2bec56fcf8638cb,
title = "Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay",
abstract = "The COBAS{\circledR} Core HEp2 ANA enzyme immune assay (EIA) was evaluated in a precision and a clinical sample study in comparison to indirect immunofluorescence assay (IFA) on HEp2-cells. In the precision study the COBAS{\circledR} Core EIA yielded intraassay coefficient variations (CVs) mostly below 9{\%}, and interassay CVs between 4.7{\%} and 10.4{\%}. When comparing the COBAS{\circledR} Core EIA to IFA, the results corresponded well in healthy subjects, systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. In the case of Sjogren's syndrome and scleroderma patients the COBAS{\circledR} Core EIA yielded a lower rate of positive results compared to IFA. This discrepancy may be explained by the lack of detection of autoantibodies to nuclear antigens that can be identified only by IFA due to their compartimentalization and higher localized antigen density in HEp2 cells. The discrepancies in the group of dermato/polymyositis patients are due to the fact that the EIA contains mainly nuclear antigens and was able to detect only antibodies against the cytoplasmic Jo1 antigen that was added to the HEp2 nuclear extract. Routine sera were also evaluated; good agreement was found in sera from patients attending tertiary reference centres for autoimmune diseases but a higher number of discrepancies was reported in sera from unselected populations.",
keywords = "Antinuclear antibodies, Enzyme immunoassay, Systemic autoimmune diseases",
author = "Bayer, {P. M.} and S. Bauerfeind and J. Bienvenu and N. Fabien and Frei, {P. C.} and B. Gilburd and Heide, {K. G.} and M. Hoier-Madsen and Meroni, {P. L.} and Monier, {J. C.} and G. Monneret and P. Panzeri and Y. Shoenfeld and F. Spertini and A. Wiik",
year = "1999",
month = "8",
doi = "10.1006/jaut.1999.0298",
language = "English",
volume = "13",
pages = "89--93",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Multicenter evaluation study on a new HEP2 ANA screening enzyme immune assay

AU - Bayer, P. M.

AU - Bauerfeind, S.

AU - Bienvenu, J.

AU - Fabien, N.

AU - Frei, P. C.

AU - Gilburd, B.

AU - Heide, K. G.

AU - Hoier-Madsen, M.

AU - Meroni, P. L.

AU - Monier, J. C.

AU - Monneret, G.

AU - Panzeri, P.

AU - Shoenfeld, Y.

AU - Spertini, F.

AU - Wiik, A.

PY - 1999/8

Y1 - 1999/8

N2 - The COBAS® Core HEp2 ANA enzyme immune assay (EIA) was evaluated in a precision and a clinical sample study in comparison to indirect immunofluorescence assay (IFA) on HEp2-cells. In the precision study the COBAS® Core EIA yielded intraassay coefficient variations (CVs) mostly below 9%, and interassay CVs between 4.7% and 10.4%. When comparing the COBAS® Core EIA to IFA, the results corresponded well in healthy subjects, systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. In the case of Sjogren's syndrome and scleroderma patients the COBAS® Core EIA yielded a lower rate of positive results compared to IFA. This discrepancy may be explained by the lack of detection of autoantibodies to nuclear antigens that can be identified only by IFA due to their compartimentalization and higher localized antigen density in HEp2 cells. The discrepancies in the group of dermato/polymyositis patients are due to the fact that the EIA contains mainly nuclear antigens and was able to detect only antibodies against the cytoplasmic Jo1 antigen that was added to the HEp2 nuclear extract. Routine sera were also evaluated; good agreement was found in sera from patients attending tertiary reference centres for autoimmune diseases but a higher number of discrepancies was reported in sera from unselected populations.

AB - The COBAS® Core HEp2 ANA enzyme immune assay (EIA) was evaluated in a precision and a clinical sample study in comparison to indirect immunofluorescence assay (IFA) on HEp2-cells. In the precision study the COBAS® Core EIA yielded intraassay coefficient variations (CVs) mostly below 9%, and interassay CVs between 4.7% and 10.4%. When comparing the COBAS® Core EIA to IFA, the results corresponded well in healthy subjects, systemic lupus erythematosus, mixed connective tissue disease and rheumatoid arthritis. In the case of Sjogren's syndrome and scleroderma patients the COBAS® Core EIA yielded a lower rate of positive results compared to IFA. This discrepancy may be explained by the lack of detection of autoantibodies to nuclear antigens that can be identified only by IFA due to their compartimentalization and higher localized antigen density in HEp2 cells. The discrepancies in the group of dermato/polymyositis patients are due to the fact that the EIA contains mainly nuclear antigens and was able to detect only antibodies against the cytoplasmic Jo1 antigen that was added to the HEp2 nuclear extract. Routine sera were also evaluated; good agreement was found in sera from patients attending tertiary reference centres for autoimmune diseases but a higher number of discrepancies was reported in sera from unselected populations.

KW - Antinuclear antibodies

KW - Enzyme immunoassay

KW - Systemic autoimmune diseases

UR - http://www.scopus.com/inward/record.url?scp=0032765522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032765522&partnerID=8YFLogxK

U2 - 10.1006/jaut.1999.0298

DO - 10.1006/jaut.1999.0298

M3 - Article

C2 - 10441172

AN - SCOPUS:0032765522

VL - 13

SP - 89

EP - 93

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 1

ER -